Three million people worldwide are taking the new, heavily advertised anti-cholesterol drugs Zetia and Vytorin, despite a lack of clinical evidence that they reduce cardiovascular disease or heart attacks, or help patients live longer. Vytorin and Zetia brought in $5.2 billion last year for Merck and Schering-Plough, placing them among the best-selling drugs in the world. The Food and Drug Administration approves many drugs based on whether they perform a specific action, like lowering cholesterol, without requiring long-term trials on whether they extend life or lower disease risks. Other FDA-approved drugs have been found to be ineffective or even dangerous.
Best-Selling Cholesterol Drugs Found Ineffective
A civil jury in Maine has awarded $25m to a woman whose teenage daughter died from...
There is not enough evidence to confirm that Tylenol causes autism but the pain medication should...
At just 13 years old, Kevin Tang is establishing himself in the world of science and...
